To,

Saturday, August 12, 2023

Department of Corporate Service

BSE Limited,

Registered Office: Floor 25, P. J. Towers,

Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.

T: 2272 1233 / 1234 | F: 2272 3121 / 3719 | www.bseindia.com

Subject

: Approval of Standalone Un-Audited Financial Results for the quarter ended June 30, 2023 along with Declaration and Auditor's Report.

Reference: Centenial Surgical Suture Ltd. | Scrip Code: 531380

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter ended June 30, 2023.
- Limited Review Report for the quarter ended June 30, 2023.

Kindly take the same on your record.

Sincerely,

For CENTENIAL SURGICAL SUTURE LTD.



by MAHIMA Date: 2023.08.12 15:56:35 +05'30'

Mahima BATHWAL Membership No. ACS A35069

Company Secretary & Compliance Officer

Enclosures: as mentioned above.

Registered Office F-29, MIDC, Murbad, Thane 421401. MAHARASHTRA. **C**912524222905 Fax 912524222905

Manufacturing Facility

B-17 / F-29 / F-22 MIDC, Murbad, Thane 421401. MAHARASHTRA. \$\bigcelle{\cupselon} 2524223200 \quad \text{Fax 912524 222872}

Sales Office - Mumbai 1st Floor, Palai Complex CHS Ltd., Bhandarkar Road, Matunga (East), Mumbai 400019. MAHARASHTRA. **1**912224102876 Fax 912224161261

☐ Sales Office - Bengaluru No.12/42, Udhani Layout, Off. Cambridge Road, Halasur, Bengaluru 560008. **KARNATAKA.** \$\circ\$ 9180 25577791 Fax 9180 25577792

☐ Sales Office - Kolkata Flat No. N-1, Ground Floor, 385, Purbachal, Kalitala Road, P.S.Kasba, Kolkata 700078. WEST BENGAL. **4** 91 3324844875 Fax 91 3324844875

continuation sheet

Statement of Standalone Un-Audited Financial Results for the Quarter ended June 30, 2023

(Rs. In Lakhs, unless otherwise stated)

	Particulars	Quarter ended			Year ended
Sr. No.		30/06/2023	31/03/2023	30/06/2022	31/03/2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Revenue from Operations	1365.91	1301.83	1349.22	5265.53
11	Other Income	0.60	2.89	0.02	12.94
III	Total Revenue (I + II)	1366.51	1304.72	1349.24	5278.47
IV	Expenses:				
	(a) Cost of Material Consumed	469.71	483.46	560.17	2025.96
	(b) Purchase of Stock-in-Trade				
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	23.57	47.04	(54.61)	(19.25)
	(d) Employee Benefits Expenses	290.39	216.72	274.93	1118.74
	(e) Finance Cost	48.46	51.66	37.28	166.41
	(f) Depreciation and Amortisation Expenses	30.01	30.95	33.86	129.96
		465.39	445.30	457.72	1710.36
	(g) Other Expenses	1327.53	1275.13	1309.35	5132.18
٧	Total Expenses (IV)	38.98	29.59	39.89	146.29
	Profit / (Loss) before Exceptional items and Tax (III - IV)	30.30	23.33	33.03	140.23
VI	Exceptional Items	38.98	29.59	39.89	146.29
VII	Profit / (Loss) Before Tax (V - VI)	30.30	29.09	33.03	140.23
VIII	Tax Expense:	0.01	15.54	10.04	44.00
	(1) Current Tax	9.81	15.54	10.04	44.92 1.17
	(2) Deferred tax		45.54	10.04	
	Total Tax Expenses	9.81	- 15.54	10.04	46.09
IX	Profit / (Loss) for the period from Continuing Operations (VII -VIII)	29.17	14.05	29.85	100.20
X	Profit / (Loss) from Discontinued Operations		•	*	
XI	Tax expenses of Discontinued Operations			-	
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	•		•	-
XIII	Profit / (Loss) for the period (IX+XII)	29.17	14.05	29.85	100.20
XIV	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss		1.0		
	(ii) Income tax relating to items that will not be reclassified to profit or loss		- 1 E y 2		
	B. (i) Items that will be reclassified to profit or loss		•	-	20
	(ii) Income tax relating to items that will be reclassified to profit or loss	•			(11.61
χV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	29.17	14.05	29.85	88.59
XVI	Details of Equity share capital				
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00
XVII	Earnings Per Equity Share (for Continuing operation) :				
	(a) Basic	0.80	0.38	0.82	2.43
	(b) Diluted	0.80	0.38	0.82	2.43
XVIII	Earnings Per equity share (for Discontinued operation):				
	(a) Basic		2 2		-
	(b) Diluted		-		-
XIX	Earnings Per Equity Share (for Discontinued & Continuing operation):				
AIA	(a) Basic	0.80	0.38	0.82	2.43
	(b) Diluted	0.80		0.82	2.43



Notes:

- 1). The Company has one reportable business segment "Medical Devices".
- 2). The above Statement of Standalone Un-Audited Financial Results for the quarter ended June 30, 2023 ("Statement") is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on August 12, 2023. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory
 Auditors have carried out a Limited Review of the Standalone Un-Audited Financial Results for the quarter ended June 30, 2023.
- The Standalone Un-Audited Financial Results for the quarter ended June 30, 2023 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

for and on behalf of the Board of Directors of

for CENTENIAL SURGICAL SUTURE LTD.

VIJAY KALIDAS MAJREKAR Digitally signed by VIJAY KALIDAS MAIREKAR

MAJREKAR Date: 2023.08.12 15:04:19 +05'30'

Vijay MAJREKAR Managing Director & Chief Executive Officer

DIN: 00804808

SURGICAL SURGICA SURGIC

Place : Mumbai, Maharashtra Date : August 12, 2023

Mahesh Chandra & Associates

Chartered Accountants

Independent Auditor's Review Report on Standalone Un-Audited Financial Results of the Company for the Quarter ended June 30, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements [LODR]) Regulations, 2015, as amended.

Review Report to

The Board of Directors of CENTENIAL SURGICAL SUTURE LTD.

Registered Office: F-29, M.I.D.C., Murbad, Thane 421401, MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of **CENTENIAL SURGICAL SUTURE LIMITED** ("the Company") for the quarter ended June 30, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR), Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- b. This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on August 12, 2023 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- c. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. MAHESH CHANDRA & ASSOCIATES

CHARTERED ACCOUNTANTS

[Firm Registration No.: 112334W]

RAJESH Digitally signed by RAJESH BOHRA Date: 2023.08.12 16:08:35 +05'30'

RAJESH BOHRA

Partner

[Membership No.102587] UDIN: 23102587BGVCZY4628

Date : August 12, 2023

Place: Mumbai, MAHARASHTRA.